Ruti Aga Handed Six-Year Ban: A Family Member Forged the Prescription, and a Glucocorticoid Built the Double Sanction

The Athletics Integrity Unit (AIU) announced on Thursday that Ethiopian marathon runner Ruti Aga has been banned for six years. The sanction is built by stacking two separate violations in a single case. The first is a doping violation — a prohibited substance was found in a sample taken at a half marathon in China in March. The second, and far more consequential, is that a forged medical prescription was presented during the investigation as proof of treatment. According to the AIU statement, the prescription was not written by a registered doctor but by a member of the athlete's own family, who holds no medical registration. That family member told investigators he had used "an old prescription pad from a former workplace." The clinic named on the prescription, however, does not exist. On its own this reads like an isolated detail. In reality it points to an ecosystem in East African road racing where an athlete's medical support is often informal and personal rather than institutional. The Arithmetic of the Sanction The six-year figure makes sense once you break it down. Two years for the presence of a prohibited substance, and four years for tampering with documents — six years in total. That split is revealing. A two-year sanction is typically imposed when the substance falls in the "specified" category and deliberate cheating has not been established, meaning the panel did not find intent fully proven on the substance charge. But the additional four years shows the panel treated the forgery as fully culpable and rejected the "no significant fault" mitigation that would otherwise have reduced the presence sanction. A Technical Correction: This Is Not a Steroid Media coverage of this case contains a significant error. Methylprednisolone has been described as a "prohibited steroid" and as something WADA classes as performance enhancing. That description is technically wrong. Methylprednisolone is a glucocorticoid, falling under class S9 of the WADA Prohibited List — not an anabolic steroid, which is class S1. The distinction is not semantic; it changes the legal direction of the entire case. Under the current Prohibited List, glucocorticoids are prohibited in-competition only, and only when administered by injection, orally, or rectally. A therapeutic dose injected into the knee out of competition is entirely legal. It becomes a violation only if residues are present in a sample taken in competition. In road racing, the testing window opens at 23:59 the night before the race. That means an athlete who received an injection days earlier, with the drug not yet fully cleared, will be caught. This case is not about steroid use. It is about route of administration and the timing calculation. The Knee Injury and the Chain of Forgery Aga told investigators she took the medication to treat a knee injury. That explanation is entirely credible on medical grounds. Intra-articular or peri-articular methylprednisolone for knee inflammation is standard sports-medicine practice in distance runners. And that credibility is precisely the tragedy here. If the treatment had genuinely happened and been documented, it could have been proven with real records. The decision to forge a prescription is itself evidence that real records did not exist — or did not exist at all. Investigators found three separate verification failures. First, the clinic named on the prescription does not exist. Second, the person who wrote it holds no medical registration — he is a family member. Third, that person offered the excuse of an "old prescription pad," and the clinic whose pad it supposedly was explicitly denied any connection to him. This was not a clerical slip. A whole story was fabricated. The Forgery Destroyed the Only Defence Available This is where the damage becomes clear. Because glucocorticoids are prohibited only in-competition, Aga had a legitimate defence available — timing of the dose, route of administration, and medical necessity could all have been presented to show this was treatment, not an attempt to enhance performance. A competent defence team, armed with genuine medical records and a coherent timeline, could have argued the presence charge down to a no-fault or no-significant-fault finding, sharply reducing or even effectively eliminating the sanction — and no tampering charge would have been brought at all. By forging the prescription, she closed off the one path that could have worked. The Real Career Stake In career terms, Aga was no ordinary runner. She won the 2026 Tokyo Marathon, a World Marathon Majors race. Before that she finished second at the 2026 Berlin Marathon. In all she has three second-place finishes at World Marathon Majors events. By any measure this is the record of a genuinely elite marathoner. Running in the 2:18 to 2:20 range, Aga was part of the generation that lifted the standard of women's marathoning altogether. One important nuance needs stating. The violation is anchored to a March race that took place after 2026. Unless earlier use is established, results before that date are not automatically annulled. The 2026 Tokyo title and her earlier results therefore survive. The AIU statement, however, does not spell out the scope of disqualification. A Return at 38? Aga is 32. When the six-year ban that began on 10 September expires, she will be about 38. In the marathon, women typically peak between 28 and 32 and begin a gradual decline after that. A ban imposed at 32 therefore removes her from the 2028 Olympic cycle entirely and, in practical terms, ends her elite career. Calling this a sanction understates it. It is a career termination. Competition inside Ethiopian women's marathoning is so deep that a 2:18 runner cannot assume a national team place. A 38-year-old with a doping record on file has no realistic selection path at all. That is the harshest and truest aspect of this case. At national-team level, Aga's removal does not affect Ethiopia's medal capacity by any measurable margin. Her three Major second places were commercial-tier results, not championship conversions. The Medical Support Question The most troubling question in the whole affair is why an elite athlete did not have a credentialed team physician. If the knee treatment had genuinely occurred and been documented, two routes were open — either obtain a Therapeutic Use Exemption, or observe the drug's washout period and allow enough time before competition. Neither happened. This is not only an athlete's failure. It is the failure of a system in which athletes make these decisions alone, with no institutional support when a crisis arrives. The four-year tampering sanction did not come from a document alone. It came from statements made during an investigative interview. That raises the question of what an athlete was led to say during questioning, and in what language. Language and translation in AIU interviews with Ethiopian athletes have been a recurring point of contention. It would be premature to claim the same happened here, but it is fair to ask whether Aga understood what penalty presenting a false prescription could carry. Chinese Label Races and Appearance Fees The race where the sample was collected was a half marathon in China, and Aga won it. Her time, splits and field strength are not given in public reporting, so no comment on the performance is possible. What is clear is that a race at that level involves an elite women's field and both out-of-competition and in-competition testing. The Chinese label-race circuit has become an attractive, low-risk income tier for East African marathoners between Majors. That is where a real irony sits. The appearance-fee economy and the testing economy are now colliding in the same races. Where the money is largest and the elite fields deepest, AIU testing is also concentrated. Integrity risk on results from this tier will only rise. The Chinese label circuit is now a high-scrutiny zone. The New Enforcement Frontier The most important signal here is that the enforcement frontier has shifted from "detection" to "document verification." Aga's case is not an outlier; it belongs to a family of East African road-racing cases in which an initial substance violation is compounded by a fabricated or altered explanation. The pattern suggests that many athletes have no option but the same informal medical network when crisis hits. If that is right, more such cases will follow, because the same networks serve the same training clusters. Proportionality A six-year ban for a glucocorticoid is a striking outcome, particularly because the substance has no proven endurance benefit. The number will be cited both ways: as evidence of AIU rigour, and as evidence of inconsistent, excessive action against African road runners. That debate is legitimate and will intensify. One fact belongs in it — this sanction was not imposed for the substance. It was imposed for the document. The Appeal Route Legally, an appeal is open. A Court of Arbitration for Sport appeal is typically possible within about 21 days of the reasoned decision. But the odds here are poor, because the forgery finding rests on documents and is very hard to overturn. Who wrote the prescription, where it came from, and what the clinic had to do with it are factual questions, and the facts are clear. What Will Be Annulled The statement does not say so explicitly, but under standard AIU practice the result and prize money from the March race should be treated as annulled, since the competition at which the sample was collected is automatically disqualified. Ranking points accrued after that date also go. This effect is not written out in the statement, but it is the standard procedure. Results from before 2026 are unaffected by default. The Federation's Silence One detail deserves attention — no statement has emerged from the Ethiopian federation. All available information comes from the AIU alone. It is also unclear whether anyone beyond the family member — an agent or manager — was investigated. If someone helped prepare or accepted that forged document, where did that responsibility go? The question is unanswered, and that silence is the case's biggest institutional weakness. What a Proper Defence Would Have Achieved For comparison, consider what a correct path would have produced. Genuine medical records, a clear account of route and timing, and proof of medical necessity could have taken the presence charge to a no-fault finding, with a sanction either very light or limited to a reprimand. And no tampering charge would have followed. In the best case, a TUE-compliant treatment plan with correct timing would have produced no case at all. The real damage came not from the drug but from the piece of paper created to prove the drug. The Lesson The lesson is not that glucocorticoids are dangerous. The lesson is that reliance on informal medical arrangements can one day cost an athlete an entire career. The knee injury was real, treatment was possible, and the legal route was open. What went wrong was the attempt to fill the absence of documentation with a lie. The six-year ban is the price of that single decision — not the drug's price, the prescription's. Conclusion At 32, with three Major podiums and a Major title, Aga's name will stay in the record of women's marathoning. It will not, however, be remembered the way a runner would want. The case is a clear message to sports administrators too: tampering with documents closes the one path a defence might have had. And it shows that the road-racing economy is growing far faster than the medical support available to the athletes who drive it. Until that gap closes, such prescriptions will keep being written — and such bans will keep being handed down.